Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. A marketing authorization application (MAA) has also been filed for axi-cel for the treatment of relapsed/refractory DLBCL, TFL and PMBCL with the European Medicines Agency (EMA), representing the first submission in Europe for a CAR T therapy. The FDA has set a target action date of Novemunder the Prescription Drug User Fee Act (PDUFA). It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. This Smart News Release features multimedia. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. & SANTA MONICA, Calif.-(BUSINESS WIRE)- Gilead Sciences, Inc. Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs -įOSTER CITY, Calif. Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation. Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. Immediately Positions Gilead as a Leader in Cell Therapy. Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |